Cardiovascular Diagnostics forms holding company:
This article was originally published in Clinica
Cardiovascular Diagnostics' shareholders have approved a holding company reorganisation, which sees Cardiovascular becoming a wholly-owned subsidiary of the new holding company, PharmaNetics. Each share of Cardiovascular has been converted into PharmaNetics shares, which will be traded on the Nasdaq. No changes have been made to the company's management or board of directors. The Raleigh, North Carolina-based company makes rapid diagnostics to assess blood clot formation and dissolution.
You may also be interested in...
South Korea’s HLB has begun a new growth phase by taking over US-based clinical stage biotech firm Immunomic Therapeutics. Through the acquisition, it is poised to add new pipeline assets including a Phase II vaccine therapy for glioblastoma and proprietary lysosomal targeting technology.
Less-invasive technologies to treat benign prostatic hyperplasia are fast becoming viable alternatives to medication and surgery. Here's what one researcher in the area, Steven Raman, had to say about the new options.
Novartis’s first digital innovation hub in Asia is launched in India, where the Swiss company hopes to ally with partners to deliver digital solutions for patients at scale.